-
Something wrong with this record ?
Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study
M. Dusejovska, B. Stankova, M. Vecka, J. Rychlíkova, M. Mokrejsova, I. Rychlík, A. Zak,
Language English Country United Arab Emirates
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Apolipoprotein B-100 blood MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Cholesterol blood MeSH
- Kidney Failure, Chronic blood diagnosis MeSH
- Dyslipidemias blood diagnosis MeSH
- Cholesterol, LDL blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoproteins blood MeSH
- Lipid Metabolism * MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Triglycerides blood MeSH
- Cholesterol, VLDL blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Patients with end-stage renal disease (ESRD) exhibit high morbidity as well as mortality for atherosclerotic cardiovascular diseases (CVD). Therefore, we investigated differences in individual lipoprotein classes and subclasses in ESRD patients under chronic high volume hemodiafiltration (HV-HDF) in comparison with a control group. We also assessed the prognosis of these patients and analyzed these parameters after 5 years follow-up. METHODS: 57 patients and 50 controls were enrolled. We analysed high density (HDL) and low density (LDL) lipoprotein subfractions using the Quantimetrix Lipoprint(R) system. Subfractions were correlated with selected clinical-biochemical parameters including risk factors for atherosclerotic CVD at the beginning of and after 5 years follow-up. RESULTS: Fourteen patients survived the 5-year follow-up. Follow-up results revealed a shift toward smaller HDL subfractions. In lipoproteins carrying apolipoprotein B, there was a shift of cholesterol from very low density (VLDL) to intermediate density (IDL) lipoproteins and LDLs. Hypolipidaemic therapy did not influence lipoprotein profiles in HV-HDF patients. CONCLUSION: 1. HV-HDF patients exhibit specific lipid profiles with elevated triacylglycerol, low HDL and LDL and higher content of cholesterol in remnant particles (VLDL and IDL) at the expense of large LDL. HDL subfractions were linked to the number of risk factors for CVD in the control group only. 2. Baseline lipoprotein profiles did not differ between survivors and non-survivors. Non-survivors had higher CRP and lower HDL-C. 3. During the 5 year follow-up period, cholesterol in HDL particles and lipoproteins carrying apolipoprotein B redistributed in survivors towards smaller particles, thus resembling the profile of control patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013158
- 003
- CZ-PrNML
- 005
- 20190411102158.0
- 007
- ta
- 008
- 190405s2018 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1570161115666170530104143 $2 doi
- 035 __
- $a (PubMed)28554308
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Dusejovska, Magdalena $u Dialysis center Fresenius Medical Care - DS, s.r.o., Vinohrady, Srobarova 50, Prague 10, 100 00, Czech Republic. IVth Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague, U Nemocnice 2, Prague 2, 128 00, Czech Republic.
- 245 10
- $a Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study / $c M. Dusejovska, B. Stankova, M. Vecka, J. Rychlíkova, M. Mokrejsova, I. Rychlík, A. Zak,
- 520 9_
- $a BACKGROUND: Patients with end-stage renal disease (ESRD) exhibit high morbidity as well as mortality for atherosclerotic cardiovascular diseases (CVD). Therefore, we investigated differences in individual lipoprotein classes and subclasses in ESRD patients under chronic high volume hemodiafiltration (HV-HDF) in comparison with a control group. We also assessed the prognosis of these patients and analyzed these parameters after 5 years follow-up. METHODS: 57 patients and 50 controls were enrolled. We analysed high density (HDL) and low density (LDL) lipoprotein subfractions using the Quantimetrix Lipoprint(R) system. Subfractions were correlated with selected clinical-biochemical parameters including risk factors for atherosclerotic CVD at the beginning of and after 5 years follow-up. RESULTS: Fourteen patients survived the 5-year follow-up. Follow-up results revealed a shift toward smaller HDL subfractions. In lipoproteins carrying apolipoprotein B, there was a shift of cholesterol from very low density (VLDL) to intermediate density (IDL) lipoproteins and LDLs. Hypolipidaemic therapy did not influence lipoprotein profiles in HV-HDF patients. CONCLUSION: 1. HV-HDF patients exhibit specific lipid profiles with elevated triacylglycerol, low HDL and LDL and higher content of cholesterol in remnant particles (VLDL and IDL) at the expense of large LDL. HDL subfractions were linked to the number of risk factors for CVD in the control group only. 2. Baseline lipoprotein profiles did not differ between survivors and non-survivors. Non-survivors had higher CRP and lower HDL-C. 3. During the 5 year follow-up period, cholesterol in HDL particles and lipoproteins carrying apolipoprotein B redistributed in survivors towards smaller particles, thus resembling the profile of control patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a apolipoprotein B-100 $x krev $7 D053299
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a cholesterol $x krev $7 D002784
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a VLDL-cholesterol $x krev $7 D015243
- 650 _2
- $a dyslipidemie $x krev $x diagnóza $7 D050171
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronické selhání ledvin $x krev $x diagnóza $7 D007676
- 650 12
- $a metabolismus lipidů $7 D050356
- 650 _2
- $a lipoproteiny $x krev $7 D008074
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a triglyceridy $x krev $7 D014280
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Stankova, Barbora $u IVth Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague, U Nemocnice 2, Prague 2, 128 00, Czech Republic.
- 700 1_
- $a Vecka, Marek $u IVth Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague, U Nemocnice 2, Prague 2, 128 00, Czech Republic.
- 700 1_
- $a Rychlíkova, Jana $u IVth Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague, U Nemocnice 2, Prague 2, 128 00, Czech Republic.
- 700 1_
- $a Mokrejsova, Magdalena $u Ist Department of Medicine, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 00, Czech Republic.
- 700 1_
- $a Rychlík, Ivan $u Dialysis center Fresenius Medical Care - DS, s.r.o., Vinohrady, Srobarova 50, Prague 10, 100 00, Czech Republic. Ist Department of Medicine, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10, 100 00, Czech Republic.
- 700 1_
- $a Zak, Ales $u IVth Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital Prague, U Nemocnice 2, Prague 2, 128 00, Czech Republic.
- 773 0_
- $w MED00007897 $t Current vascular pharmacology $x 1875-6212 $g Roč. 16, č. 3 (2018), s. 298-305
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28554308 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411102215 $b ABA008
- 999 __
- $a ok $b bmc $g 1392468 $s 1051463
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 16 $c 3 $d 298-305 $i 1875-6212 $m Current vascular pharmacology $n Curr Vasc Pharmacol $x MED00007897
- LZP __
- $a Pubmed-20190405
